ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2021
Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Objective Criteria for Subtle Cognitive Decline in Aging and Preclinical Alzheimer Disease: A Systematic Review.Neurology · 2025Pooled it
- [Progress on prognostic assessment methods for mild cognitive impairment].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Review
- Association of Fractional Anisotropy in White Matter Bundles with Plasma Biomarkers of Neurodegeneration and Glial Reactivity in Individuals with Cognitive Complaints without dementia.Research square · 2026Article
- Alzheimer's disease plasma biomarkers are associated with cognitive performance among Hispanic/Latino adults.Communications medicine · 2025Article
- Disclosure of Alzheimer's disease blood-based biomarker results in a primary care setting: Opportunities and challenges.The journal of prevention of Alzheimer's disease · 2025Review
- Presynaptic loss and axonal degeneration synergistically correlate with longitudinal neurodegeneration and cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment.Neuropsychology · 2025Article
- Associations of Post-Traumatic Stress Disorder and Objective Subtle Cognitive Difficulties in Cognitively Unimpaired Older Veterans.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2024Article
- Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting study.Alzheimer's research & therapy · 2024Article
- Joint effect of testosterone and neurofilament light chain on cognitive decline in men: The Shanghai Aging Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer's disease.Molecular neurodegeneration · 2024Article
- Heterogeneity of cognitive impairments in myotonic dystrophy type 1 explained by three distinct cognitive profiles.Journal of neurology · 2024Article
- Plasma biomarkers for Alzheimer's and related dementias: A review and outlook for clinical neuropsychology.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2024Review
- Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Blood Biomarkers of Alzheimer's Disease and Cognition: A Literature Review.Biomolecules · 2024Review
- Longitudinal assessment of plasma biomarkers for early detection of cognitive changes in subjective cognitive decline.Frontiers in aging neuroscience · 2024Article
- Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study.European journal of neurology · 2024Article
- The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- Impairment of delayed recall as a predictor of amnestic mild cognitive impairment development in normal older adults: a 7-year of longitudinal cohort study in Shanghai.BMC psychiatry · 2023Article
- Plasma neurofilament light and brain volumetric outcomes among middle-aged urban adults.Neurobiology of aging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
introductionNeurofilament light (NFL) reflects neuroaxonal damage and is implicated in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Little is known about NFL in pre-MCI stages, such as in individuals with objectively-defined subtle cognitive decline (Obj-SCD).
methodsTwo hundred ninety-four participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent baseline blood draw and serial neuropsychological testing over 5 years of follow-up.
resultsIndividuals with Obj-SCD and MCI showed elevated baseline plasma NFL relative to the cognitively normal (CN) group. Across the sample, elevated NFL predicted faster rate of cognitive and functional decline. Within the Obj-SCD and MCI groups, higher NFL levels predicted faster rate of decline in memory and preclinical AD composite score compared to the CN group. DISCUSSION: Findings demonstrate the utility of plasma NFL as a biomarker of early AD-related changes, and provide support for the use of Obj-SCD criteria in clinical research to better capture subtle cognitive changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.